High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

Journal of Clinical Oncology

Volumn 15, Issue 11, 1997, Pages 3363-3367

  Disis, Mary L ^a   Pupa, Serenella M ^a   Gralow, Julie R ^a   Dittadi, Ruggero ^a   Menard, Sylvie ^a   Cheever, Martin A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER IMMUNOLOGY; CANCER STAGING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0030657467     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.11.3363     Document Type: Article

References (18)

1. Slamon D, Clark G, Wong S, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Gusterson B, Gelber R, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
3. Rilke F, Colnaghi M, Cascinelli N, et al: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44-49, 1991
4. Disis ML, Cheever MA: Oncogenic proteins as tumor antigens. Curr Opin Immunol 5:637-642, 1996
5. Canevari S, Pupa SM, Menard S: 1975-1995 Revised anti-cancer serological response: Biological significance and clinical implications. Ann Oncol 7:227-232, 1996
6. Pupa SM, M'enard S, Andreola S, et al: Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 53:5864-5866, 1993
7. Disis ML, Calenoff E, McLaughlin G, et al: Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16-20, 1994
8. Fisk B, Blevins TL, Wharton JT, et al: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109-2117, 1995
9. Peoples GE, Goedegebuure PS, Smith R, et al: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432-436, 1995
10. Mariani-Costantini R, Barbanti P, Colnaghi MI, et al: Reactivity of a monoclonal antibody with tissues and tumors from human breast: Immunohistochemical localization of a new antigen and clinico-pathologic correlations. Am J Pathol 115:47-56, 1984
11. Hsieh-Ma ST, Eaton AM, Shi T, et al: In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III. Cancer Res 52:6832-6839, 1992
12. Bacus SS, Stancovski I, Huberman E, et al: Tumor-inhibitory monoclonal antibodies to the HER-2/neu receptor induce differentiation of human breast cancer cells. Cancer Res 52:2580-2589, 1992
13. Katsumata M, Okudaira T, Samanta A, et al: Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1:644-648, 1995
14. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer (see comments). J Clin Oncol 14:737-744, 1996
15. Leitzel K, Teramoto Y, Sampson E, et al: Elevated soluble c-erb-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10:1436-1443, 1992
16. Pupa SM, Bufalino R, Invernizzi AM, et al: Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 14:85-94, 1996
17. Menard S, Pupa SM, Casalini P, et al: Relationship of histological grade, c-erbB-2 expression and inflammatory infiltrate to prognosis in breast carcinoma. J Clin Oncol 14:2406-2407, 1996
18. Weiner LM, Clark JI, Davey M, et al: Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 55:4586-93, 1995